Overcoming the barriers to xenotransplantation: Prospects for the future

Academic Article

Abstract

  • Cross-species transplantation (xenotransplantation) has immense potential to solve the critical need for organs, tissues and cells for clinical transplantation. The increasing availability of genetically engineered pigs is enabling progress to be made in pig-to-nonhuman primate experimental models. Potent pharmacologic immunosuppressive regimens have largely prevented T-cell rejection and a T-cell-dependent elicited antibody response. However, coagulation dysfunction between the pig and primate is proving to be a major problem, and this can result in life-threatening consumptive coagulopathy. This complication is unlikely to be overcome until pigs expressing a human 'antithrombotic or 'anticoagulant gene, such as thrombomodulin, tissue factor pathway inhibitor or CD39, become available. Progress in islet xenotransplantation has been more encouraging, and diabetes has been controlled in nonhuman primates for periods in excess of 6 months, although this has usually been achieved using immunosuppressive protocols that might not be clinically applicable. Further advances are required to overcome the remaining barriers. © 2010 Expert Reviews Ltd.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Author List

  • Ekser B; Cooper DK
  • Start Page

  • 219
  • End Page

  • 230
  • Volume

  • 6
  • Issue

  • 2